1

Centers for Disease Control and Prevention

National Center for Immunization and Respiratory Diseases

Maternal/Pediatric Respiratory Syncytial Virus (RSV) 

Work Group

Sarah S. Long, MD

Chair, Maternal/Pediatric RSV Work Group 

ACIP General Meeting

August 3, 2023
2

Work group members (External)

ACIP Members

Sarah Long (chair)

Pablo Sanchez

Oliver Brooks

Camille Kotton

Consultants

Cody Meissner (Dartmouth Geisel School of Medicine)

Helen Chu (University of Washington)

Natasha Halasa (Vanderbilt University)

Denise Jamieson (Emory University School of Medicine)

Daniel Feikin (World Health Organization)

Carol Baker (University of Texas Health Science Center)

Kevin Ault (Western Michigan University) Liaisons

James McAuley (IDSA)

Patsy Stinchfield (NFID)

Brenna L. Hughes (ACOG)

Nicole Chaisson (AAFP)

Sean O’Leary (AAP)

Jennifer Schuster (PIDS)

Molly Howell (AIM)

GRADE/EtR Consultants

Doug Campos-Outcalt

Rebecca Morgan

Ex Officio Members

Rachel Zhang (FDA-CBER)

Nicholas Geagan (FDA-CBER)

Judy Beeler (FDA-CBER)

Yodit Belew (FDA-CDER)

Prabha Viswanathan (FDA-CDER)

Sonnie Kim (NIH-NIAID)

April Killikelly (Public Health Agency of Canada)

Winnie Siu (Public Health Agency of Canada)

Valerie Marshall (OIDP/OASH)

Jessica Lee (CMS/CMCS)

Terry Dalle-Tezze (HRSA)

Lucia Lee (FDA-CBER)

Robin Wisch (FDA-CBER)
3

Work group members (CDC)

Amber Winn

Chris Taylor

Tami Skoff

Angie Campbell

Michael Melgar

Amanda Payne

Nicole Dowling

Noelle Molinari

Claire Midgley

Fiona Havers

Pragna Patel

Andrea Sharma

Amadea Britton

Ruth Link-Gelles

Danielle Moulia

Megan Wallace

Monica Godfrey

Karen Broder

Naomi Tepper

Heidi Moline

CDC ACIP Staff

Melinda Wharton

Stephanie Thomas

Jessica MacNeil

Hannah Rosenblum

Derrell Powers

Raigan Wheeler

Sally Ezra

Elizabeth Greene

Manisha Patel

Tom Shimabukuro

Demorah Hayes

Latifah Boyce

CDC

Katherine Fleming-Dutra (co-lead)

Jefferson Jones (co-lead)

Meredith McMorrow

Mila Prill

Natalie Thornburg

Aron Hall

Ismael Ortega-Sanchez

Melissa Coughlin

Jamison Pike

Lauren Roper

A. Patricia Wodi

Neil Murthy

Christine Olson

Anne Hause

Andrew Leidner

David Shay

Sarah Meyer
4

▪ Epidemiology and burden of RSV in infants

▪ Virology and immunology of RSV

▪ Safety and efficacy of nirsevimab

▪ Cost effectiveness analysis for nirsevimab – CDC model

▪ Cost effectiveness analysis for nirsevimab – Comparison with manufacturer model

▪ Evidence to Recommendations framework for nirsevimab

▪ Clinical considerations for nirsevimab

Previous maternal/pediatric RSV ACIP presentations on 

nirsevimab
5

Agenda: Thursday August 3, 2023

▪ Evidence to Recommendations 

Framework for nirsevimab

▪ Nirsevimab implementation 

considerations

▪ Clinical considerations for nirsevimab

▪ Workgroup considerations and proposed 

recommendations and voting language 

▪ Vaccines for Children Resolution

Dr. Jefferson Jones (CDC)

Dr. Georgina Peacock (CDC)

Dr. Jefferson Jones (CDC)

Dr. Jefferson Jones (CDC)

Dr. Jeanne Santoli (CDC)
6
7

▪ Infants aged <8 months born during or entering their first RSV season are 

recommended to receive one dose of nirsevimab (50 mg for infants <5 kg and 100 

mg for infants ≥5 kg)

▪ Children aged 8–19 months who are at increased risk of severe RSV disease and 

entering their second RSV season are recommended to receive one dose of 

nirsevimab (200 mg) 

Proposed ACIP Voting Language